Esperion Therapeutics Announces Positive Top-Line Phase 2b Results For ETC-1002, An Investigational Therapy For Patients With Hypercholesterolemia
October 01, 2014 at 16:15 PM EDT
Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, ...